Haleos Labs Limited (NSE:HALEOSLABS)

India flag India · Delayed Price · Currency is INR
1,229.90
-4.70 (-0.38%)
Jan 22, 2026, 9:19 AM IST
-3.16%
Market Cap3.73B
Revenue (ttm)3.38B
Net Income (ttm)186.98M
Shares Out3.02M
EPS (ttm)61.84
PE Ratio19.96
Forward PEn/a
Dividend1.50 (0.12%)
Ex-Dividend DateSep 24, 2025
Volume1
Average Volume1,266
Open1,229.90
Previous Close1,234.60
Day's Range1,229.90 - 1,229.90
52-Week Range959.80 - 1,680.00
Beta0.21
RSI38.52
Earnings DateFeb 9, 2026

About Haleos Labs

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesci... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Employees 592
Stock Exchange National Stock Exchange of India
Ticker Symbol HALEOSLABS
Full Company Profile

Financial Performance

In 2024, Haleos Labs's revenue was 3.45 billion, an increase of 12.67% compared to the previous year's 3.06 billion. Earnings were 201.09 million, an increase of 121.15%.

Financial Statements